219 related articles for article (PubMed ID: 38233886)
1. The search for gastrointestinal inflammation in autism: a systematic review and meta-analysis of non-invasive gastrointestinal markers.
Mathew NE; McCaffrey D; Walker AK; Mallitt KA; Masi A; Morris MJ; Ooi CY
Mol Autism; 2024 Jan; 15(1):4. PubMed ID: 38233886
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.
Joshi S; Lewis SJ; Creanor S; Ayling RM
Ann Clin Biochem; 2010 May; 47(Pt 3):259-63. PubMed ID: 19740914
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of point-of-care test calprotectin and lactoferrin for inflammatory bowel disease among children with chronic gastrointestinal symptoms.
Holtman GA; Lisman-van Leeuwen Y; van Rheenen PF; Kollen BJ; Escher JC; Kindermann A; de Rijke YB; Berger MY
Fam Pract; 2017 Aug; 34(4):400-406. PubMed ID: 27535331
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment.
Hille A; Schmidt-Giese E; Hermann RM; Herrmann MK; Rave-Fränk M; Schirmer M; Christiansen H; Hess CF; Ramadori G
Scand J Gastroenterol; 2008 Jan; 43(1):52-8. PubMed ID: 18938774
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis.
van Rheenen PF; Van de Vijver E; Fidler V
BMJ; 2010 Jul; 341():c3369. PubMed ID: 20634346
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS.
Menees SB; Powell C; Kurlander J; Goel A; Chey WD
Am J Gastroenterol; 2015 Mar; 110(3):444-54. PubMed ID: 25732419
[TBL] [Abstract][Full Text] [Related]
8. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Intestinal Function in Children With Autism and Gastrointestinal Symptoms.
Kushak RI; Buie TM; Murray KF; Newburg DS; Chen C; Nestoridi E; Winter HS
J Pediatr Gastroenterol Nutr; 2016 May; 62(5):687-91. PubMed ID: 26913756
[TBL] [Abstract][Full Text] [Related]
10. Determination of faecal inflammatory marker concentration as a noninvasive method of evaluation of pathological activity in children with inflammatory bowel diseases.
Roszak D; Gałęcka M; Cichy W; Szachta P
Adv Med Sci; 2015 Sep; 60(2):246-52. PubMed ID: 25989184
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
12. Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a case-control study.
Barbut F; Gouot C; Lapidus N; Suzon L; Syed-Zaidi R; Lalande V; Eckert C
Eur J Clin Microbiol Infect Dis; 2017 Dec; 36(12):2423-2430. PubMed ID: 28801865
[TBL] [Abstract][Full Text] [Related]
13. Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?
Boon GJ; Day AS; Mulder CJ; Gearry RB
World J Gastroenterol; 2015 Oct; 21(40):11469-80. PubMed ID: 26523111
[TBL] [Abstract][Full Text] [Related]
14. Music therapy for autistic people.
Geretsegger M; Fusar-Poli L; Elefant C; Mössler KA; Vitale G; Gold C
Cochrane Database Syst Rev; 2022 May; 5(5):CD004381. PubMed ID: 35532041
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
Bar-Gil Shitrit A; Koslowsky B; Livovsky DM; Shitrit D; Paz K; Adar T; Adler SN; Goldin E
Scand J Gastroenterol; 2017 Mar; 52(3):328-333. PubMed ID: 27841040
[TBL] [Abstract][Full Text] [Related]
16. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
[TBL] [Abstract][Full Text] [Related]
17. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
18. No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide.
Fernell E; Fagerberg UL; Hellström PM
Acta Paediatr; 2007 Jul; 96(7):1076-9. PubMed ID: 17465982
[TBL] [Abstract][Full Text] [Related]
19. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease.
D'Incà R; Dal Pont E; Di Leo V; Ferronato A; Fries W; Vettorato MG; Martines D; Sturniolo GC
Int J Colorectal Dis; 2007 Apr; 22(4):429-37. PubMed ID: 16838143
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal manifestations and their relation to faecal calprotectin in children with autism.
Azouz HG; Zakaria NHE; Khalil AF; Naguib SM; Khalil M
Prz Gastroenterol; 2021; 16(4):352-357. PubMed ID: 34976244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
